Pigment epithelial detachment response to Aflibercept in Neovascular age-related macular degeneration refractory to Ranibizumab

Retina

Volumn 36, Issue 5, 2016, Pages 881-888

  De Massougnes, Sophie ^a   Dirani, Ali ^a   Ambresin, Aude ^a   Decugis, Doris ^a   Marchionno, Laetitia ^a   Mantel, Irmela ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

aflibercept; angiogenesis; antiangiogenic drugs; intravitreal injection; neovascular age related macular degeneration; ranibizumab; refractoriness; retinal pigment epithelial detachment; vascular endothelial growth factor; visual impairment

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; RETINA DETACHMENT; RETINA NEOVASCULARIZATION; RETINAL PIGMENT EPITHELIUM; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; TREATMENT RESPONSE; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME FACTOR; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DRUG SUBSTITUTION; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL DETACHMENT; RETINAL PIGMENT EPITHELIUM; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84966508433     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000813     Document Type: Article

References (41)

1. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65
2. Rosenfeld PJ, Brown DM, Heier JS. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431
3. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537-2548
4. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ophthalmology 2014; 121: 193-201
5. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15: 171-185
6. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol 2008; 92: 667-668
7. Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 2013; 156: 15-22
8. Cho H, Shah CP, Weber M, et al. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 2013; 97: 1032-1035
9. Ho VY, Yeh S, Olsen TW, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol 2013; 156: 23-28
10. Patel KH, Chow CC, Rathod R, et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (Lond) 2013; 27: 663-668
11. Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 2013; 156: 29-35
12. Grewal DS, Gill MK, Sarezky D, et al. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12- month results. Eye (Lond) 2014; 28: 895-899
13. Heussen FM, Shao Q, Ouyang Y, et al. Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2013; 252: 909-915
14. Wykoff CC, Brown DM, Maldonado ME, Croft DE. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol 2014; 98: 951-955
15. Gharbiya M, Iannetti L, Parisi F, et al. Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Biomed Res Int 2014; 2014: 813-825
16. Broadhead GK, Hong T, Zhu M, et al. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. Retina 2015; 35: 975-981
17. Arcinue CA, Ma F, Barteselli G, et al. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol 2015; 159: 426-436
18. Chang AA, Li H, Broadhead GK, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology 2014; 121: 188-192
19. Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013; 33: 1605-1612
20. Hariri A, Diniz B, Fou LV, et al. Quantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal aflibercept. Ophthalmic Surg Lasers Imaging Retina 2015; 46: 195-200
21. Pauleikhoff D, Löffert D, Spital G, et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol 2002; 240: 533-538
22. Punjabi OS, Huang J, Rodriguez L, et al. Imaging characteristics of neovascular pigment epithelial detachments and their response to anti-vascular endothelial growth factor therapy. Br J Ophthalmol 2013; 97: 1024-1031
23. Wolf A, Rüping J, Neubauer AS, et al. Alterations of vascular pigment epithelium detachments associated with age-related macular degeneration during upload with intravitreal ranibizumab. Retina 2013; 33: 1843-1849
24. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7: 575-583
25. Bottomley MJ, Webb NJA, Watson CJ, et al. Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is coexpressed with VEGF in synovial fluid. Clin Exp Immunol 2000; 119: 182-188
26. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 3186-3193
27. Witmer AN, Blaauwgeers HG, Weich HA, et al. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci 2002; 43: 849-857
28. Ozaki NK, Beharry KD, Nishihara KC, et al. Regulation of retinal vascular endothelial growth factor and receptors in rabbits exposed to hyperoxia. Invest Ophthalmol Vis Sci 2002; 43: 1546-1557
29. Wada M, Ogata N, Otsuji T, Uyama M. Expression of vascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization. Curr Eye Res 1999; 18: 203-213
30. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999; 155: 421-428
31. Julien S, Biesemeier A, Taubitz T, Schraermeyer U. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol 2014; 98: 813-825
32. Holz FG, Sheraidah G, Pauleikhoff D, Bird AC. Analysis of lipid deposits extracted from human macular and peripheral Bruch's membrane. Arch Ophthalmol 1994; 112: 402-406
33. Keane PA, Liakopoulos S, Ongchin SC, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008; 49: 3115-3120
34. Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 2011; 96: 14-20
35. Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008; 115: 2199-2205
36. Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol 2011; 96: 1-2
37. Eghoj MS, Sorensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2011; 96: 21-23
38. Guber J, Josifova T, Henrich PB, Guber I. Clinical risk factors for poor anatomic response to ranibizumab in neovascular agerelated macular degeneration. Open Ophthalmol J 2014; 8: 3-6
39. Mariani A, Deli A, Ambresin A, Mantel I. Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2011; 249: 1635-1642
40. Jang L, Gianniou C, Ambresin A, Mantel I. Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome. Graefes Arch Clin Exp Ophthalmol 2015; 253: 1211-1216
41. Hoerster R, Muether PS, Sitnilska V, et al. Fibrovascular pigment epithelial detachment is a risk factor for long-term visual decay in neovascular age-related macular degeneration. Retina 2014; 34: 1767-1773